Targeting the Cell Surfaceome of Aggressive Neuroendocrine Prostate Cancer

Abstract

During the course of this award, we have completed and published integrated transcriptomic and proteomic analyses of preclinical prostate cancer models that profiled cell surface antigens enriched in neuroendocrine prostate cancer (NEPC). We specifically focused on carcinoembryonic antigen-related cell adhesion molecule (CEACAM5) and L1 cell adhesion molecule (L1CAM) as two compelling targets for immune-based targeting in NEPC. We published studies using the CEACAM5 antibody-drug conjugate (ADC) labetuzumab govitecan that demonstrate activity across multiple preclinical models of NEPC including patient-derived xenograft tumors. In addition, we have investigated a chimeric antigen receptor (CAR) T cell therapy targeting L1CAM originally developed for neuroblastoma that also exhibits antigen specific antitumor activity in NEPC models. Based on these studies, we plan to translate these findings and evaluate these therapeutic strategies for men with advanced NEPC in early stage clinical trials.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 01, 2022
Accession Number
AD1190750

Entities

People

  • John K Lee

Organizations

  • Fred Hutchinson Cancer Center

Tags

DTIC Thesaurus Topics

  • Carcinoma
  • Cell Physiological Processes
  • Cells
  • Chemical Synthesis
  • Chemistry
  • Culture Techniques
  • Endocrine Cells
  • Genetics
  • Lymphocytes
  • Medical Personnel
  • Oncology
  • Stem Cells

Fields of Study

  • Biology
  • Medicine

Readers

  • Allergy and Immunology.
  • Oncology
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech